Pay in 4 interest-free payments of $45.00 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
3-[18-(2-carboxyethyl)-8
GSK-1292263 is a novel GPR119 agonist that is currently under development for the treatment of type 2 diabetes
62(12):e1800107
Z433927330 is also a partial AQP3 inhibitor (IC50
THIQ rafenib D3) 3-[18-(2-carboxyethyl)-8THIQ is the first selective agonist of the melanocortin 4 receptor (MC4R), with high affinity and potency for hMC4R (IC50=1. 2 nM, EC50=2. 1 nM) and rMC4R (IC50=0. 6 nM, EC50=2. 9 nM). THIQ maintains low potency at MC1R, MC3R and MC5R. THIQ plays a role in eliciting erectile activity in rodents. THIQ acts as a pharmacoperone of the MC4R rescuing the cell surface expression and signaling of some intracellularly retained MC4R mutants. Product
US$ 27.99
US$ 29.99
US$ 26.99